Mycotic aneurysm

From Wikidoc - Reading time: 4 min

WikiDoc Resources for Mycotic aneurysm

Articles

Most recent articles on Mycotic aneurysm

Most cited articles on Mycotic aneurysm

Review articles on Mycotic aneurysm

Articles on Mycotic aneurysm in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Mycotic aneurysm

Images of Mycotic aneurysm

Photos of Mycotic aneurysm

Podcasts & MP3s on Mycotic aneurysm

Videos on Mycotic aneurysm

Evidence Based Medicine

Cochrane Collaboration on Mycotic aneurysm

Bandolier on Mycotic aneurysm

TRIP on Mycotic aneurysm

Clinical Trials

Ongoing Trials on Mycotic aneurysm at Clinical Trials.gov

Trial results on Mycotic aneurysm

Clinical Trials on Mycotic aneurysm at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Mycotic aneurysm

NICE Guidance on Mycotic aneurysm

NHS PRODIGY Guidance

FDA on Mycotic aneurysm

CDC on Mycotic aneurysm

Books

Books on Mycotic aneurysm

News

Mycotic aneurysm in the news

Be alerted to news on Mycotic aneurysm

News trends on Mycotic aneurysm

Commentary

Blogs on Mycotic aneurysm

Definitions

Definitions of Mycotic aneurysm

Patient Resources / Community

Patient resources on Mycotic aneurysm

Discussion groups on Mycotic aneurysm

Patient Handouts on Mycotic aneurysm

Directions to Hospitals Treating Mycotic aneurysm

Risk calculators and risk factors for Mycotic aneurysm

Healthcare Provider Resources

Symptoms of Mycotic aneurysm

Causes & Risk Factors for Mycotic aneurysm

Diagnostic studies for Mycotic aneurysm

Treatment of Mycotic aneurysm

Continuing Medical Education (CME)

CME Programs on Mycotic aneurysm

International

Mycotic aneurysm en Espanol

Mycotic aneurysm en Francais

Business

Mycotic aneurysm in the Marketplace

Patents on Mycotic aneurysm

Experimental / Informatics

List of terms related to Mycotic aneurysm

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ogheneochuko Ajari, MB.BS, MS [2]; Faizan Sheraz, M.D. [3]

Overview[edit | edit source]

Mycotic aneurysm is an aneurysm that results from an infectious process that involves the arterial wall.[1] A person with a mycotic aneurysm has a bacterial infection in the wall of an artery, resulting in the formation of an aneurysm. The most common locations include arteries in the abdomen, thigh, neck, and arm. A mycotic aneurysm can result in sepsis, or life-threatening bleeding if the aneurysm ruptures. Less than 3% of abdominal aortic aneurysms are mycotic aneurysms.[2]

Historical Perspective[edit | edit source]

William Osler first used the term "mycotic aneurysm" in 1885 to describe a mushroom-shaped aneurysm in a patient with subacute bacterial endocarditis. This may create considerable confusion, since "mycotic" is typically used to define fungal infections. However, mycotic aneurysm is still used for all extracardiac or intracardiac aneurysms caused by infections, except for syphilitic aortitis.[3] The term "infected aneurysm," proposed by Jarrett and associates[4] is more appropriate, since few infections involve fungi.[5] According to some authors, a more accurate term might have been endovascular infection or infective vasculitis, because mycotic aneurysms are not due to a fungal organism.[6]

Causes[edit | edit source]

Life Threatening Causes[edit | edit source]

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.

Common Causes[edit | edit source]

Causes by Organ System[edit | edit source]

Cardiovascular No underlying causes
Chemical/Poisoning No underlying causes
Dental No underlying causes
Dermatologic No underlying causes
Drug Side Effect No underlying causes
Ear Nose Throat No underlying causes
Endocrine Diabetes mellitus
Environmental No underlying causes
Gastroenterologic No underlying causes
Genetic No underlying causes
Hematologic No underlying causes
Iatrogenic No underlying causes
Infectious Disease Acinetobacter, aspergillus, bacteroides, brucella, burkholderia pseudomallei, campylobacter, candida, clostridium perfringens, clostridium septicum, clostridium, corynebacterium, coxiella burnetii, cryptococcus, e. coli, group B streptococcal infection, haemophilus influenzae, klebsiella, lactococcus cremoris, listeria, melioidosis, methicillin-resistant staphylococcus aureus, mycobacterium tuberculosis, peptostreptococcus, propionibacterium acnes, pseudallescheria boydii, pseudomonas, rothia dentocariosa, salmonella, staphylococcus aureus, staphylococcus epidermidis, streptococcus pneumoniae, syphilis, treponema pallidum, vancomycin-intermediate staphylococcus aureus, yersinia
Musculoskeletal/Orthopedic No underlying causes
Neurologic No underlying causes
Nutritional/Metabolic No underlying causes
Obstetric/Gynecologic No underlying causes
Oncologic No underlying causes
Ophthalmologic No underlying causes
Overdose/Toxicity No underlying causes
Psychiatric No underlying causes
Pulmonary No underlying causes
Renal/Electrolyte No underlying causes
Rheumatology/Immunology/Allergy No underlying causes
Sexual No underlying causes
Trauma No underlying causes
Urologic No underlying causes
Miscellaneous No underlying causes

Causes in Alphabetical Order[edit | edit source]

The unnamed parameter 2= is no longer supported. Please see the documentation for {{columns-list}}.
2

Natural History, Complications, and Prognosis[edit | edit source]

Mycotic aneurysms account for 2.6% of aortic aneurysms.[3] For the clinician, early diagnosis is the cornerstone of effective treatment. Without medical or surgical management, catastrophic hemorrhage or uncontrolled sepsis may occur. However, symptomatology is frequently nonspecific during the early stages, so a high index of suspicion is required to make the diagnosis.[5]

Intracranial mycotic aneurysms (ICMAs) complicate about 2% to 3% of infective endocarditis (IE) cases, although as many as 15% to 29% of patients with IE have neurologic symptoms.[6]

Diagnosis[edit | edit source]

Imaging Studies[edit | edit source]

Medical Therapy[edit | edit source]

Antimicrobial Regimen[edit | edit source]

  • Empiric antimicrobial therapy[8]
  • Preferred regimen: Vancomycin 15 mg/kg IV divided q12h (trough of 15-20 mcg/mL) for 6 weeks AND (Ceftriaxone 2 g IV q24h for 6 weeks OR Piperacillin-Tazobactam 3.375 g IV q6h for 6 weeks OR Ciprofloxacin 400 mg IV q12h for 6 weeks)
  • Note: For critically ill patients, start with a vancomycin loading dose of 25 mg/kg.

References[edit | edit source]

  1. emedicine > Cerebral Aneurysm Author: Jonathan L Brisman. Coauthors: Emad Soliman, Abraham Kader, Norvin Perez. Updated: Sep 23, 2010
  2. http://www.freemd.com/mycotic-aneurysm/overview.htm Author: Stephen J. Schueler, MD; Coauthors: John H. Beckett, MD; D. Scott Gettings, MD. Updated November 13, 2011
  3. 3.0 3.1 Bayer AS, Scheld WM. Endocarditis and intravascular infections. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 5th ed. Philadelphia: Churchill Livingstone; 2000:888-892.
  4. Jarrett F, Darling RC, Mundth ED, Austen WG. Experience with infected aneurysms of the abdominal aorta. Arch Surg. 1975;110:1281-1286.
  5. 5.0 5.1 Mycotic (Infected) Aneurysm Caused by Streptococcus pneumoniae. Khosrow Afsari, et al. Infect Med. 2001;18(6)http://www.medscape.com/viewarticle/410168
  6. 6.0 6.1 http://www.gundersenhealth.org/upload/docs/Research/MedJournal/Vol6No1Endocarditis.pdf
  7. 7.0 7.1 Gomes MN, Choyke PL, Wallace RB (1992). "Infected aortic aneurysms. A changing entity". Ann Surg. 215 (5): 435–42. PMC 1242469. PMID 1616380.
  8. Gilbert, David (2014). The Sanford guide to antimicrobial therapy 2014. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808782.

Template:WH Template:WS


Licensed under CC BY-SA 3.0 | Source: https://www.wikidoc.org/index.php/Mycotic_aneurysm
4 views | Status: cached on September 30 2024 04:12:23
↧ Download this article as ZWI file
Encyclosphere.org EncycloReader is supported by the EncyclosphereKSF